RYTM
NasdaqRHYTHM PHARMACEUTICALS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$3.2M
2021
$23.6M
2022
$77.4M
2023
$130.1M
2024
$189.8M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$189.8M
Net Income$-196.5M
Gross Profit—
Oper Income$-192.0M
EPS (dil)$-3.11
Rev/sh$2.77
FCF/sh$-1.70
Book/sh$2.03
Gross M—
Oper M-101.2%
Profit M-103.6%
FCF M-61.5%
ROE-141.3%
ROA-40.9%
ROIC-99.8%
R&D/Rev88.2%
Rev Y/Y45.8%
Rev 3Y CAGR100.2%
EPS Y/Y28.3%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+6.5%
Current Ratio4.41
Quick Ratio4.16
Debt/Eq0.78
Int Coverage-9.3×
Net Debt$53.9M
Total Debt$108.2M
Cash & Eq$54.3M
Total Assets$480.2M
Oper CF$-115.7M
Capex$953,000
Free CF$-116.6M
Buybacks—
Equity$139.1M
Liabilities$210.2M
Shs Outstand0.07B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-170.1M | $-179.2M | $-184.4M | $-265.5M | $-192.0M |
| Net Income | $-69.6M | $-181.1M | $-184.7M | $-260.6M | $-196.5M |
| Diluted EPS | $-1.40 | $-3.47 | $-3.20 | $-4.34 | $-3.11 |
| Operating Cash Flow | $-146.0M | $-173.4M | $-136.2M | $-113.9M | $-115.7M |
| Free Cash Flow | $-146.4M | $-173.7M | $-136.2M | $-113.9M | $-116.6M |
COMMUNITY · $RYTM0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.